ArticleTherapeutic advances in medical oncology2022

Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial.

Wenting Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.